FustinCAS# 20725-03-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 20725-03-5 | SDF | Download SDF |
| PubChem ID | 5317435 | Appearance | Powder |
| Formula | C15H12O6 | M.Wt | 288.3 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2R,3R)-2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-2,3-dihydrochromen-4-one | ||
| SMILES | C1=CC(=C(C=C1C2C(C(=O)C3=C(O2)C=C(C=C3)O)O)O)O | ||
| Standard InChIKey | FNUPUYFWZXZMIE-LSDHHAIUSA-N | ||
| Standard InChI | InChI=1S/C15H12O6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,14-18,20H/t14-,15+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1.Fustin shows protective effects on 6-hydroxydopamine-induced neuronal cell death. |
| Targets | Beta Amyloid | AChR | ERK | cAMP | PKC |
Fustin Dilution Calculator
Fustin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.4686 mL | 17.343 mL | 34.6861 mL | 69.3722 mL | 86.7152 mL |
| 5 mM | 0.6937 mL | 3.4686 mL | 6.9372 mL | 13.8744 mL | 17.343 mL |
| 10 mM | 0.3469 mL | 1.7343 mL | 3.4686 mL | 6.9372 mL | 8.6715 mL |
| 50 mM | 0.0694 mL | 0.3469 mL | 0.6937 mL | 1.3874 mL | 1.7343 mL |
| 100 mM | 0.0347 mL | 0.1734 mL | 0.3469 mL | 0.6937 mL | 0.8672 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Norlichexanthone
Catalog No.:BCN4903
CAS No.:20716-98-7
- Neosperidin dihydrochalcone
Catalog No.:BCN5016
CAS No.:20702-77-6
- BD 1063 dihydrochloride
Catalog No.:BCC6832
CAS No.:206996-13-6
- Methysticin
Catalog No.:BCN2306
CAS No.:20697-20-5
- Tariquidar
Catalog No.:BCC3625
CAS No.:206873-63-4
- Vincristine sulfate
Catalog No.:BCN2542
CAS No.:2068-78-2
- 3,7-Di-O-methylquercetin
Catalog No.:BCN6486
CAS No.:2068-02-2
- Pedatisectine F
Catalog No.:BCN4902
CAS No.:206757-32-6
- Ecliptasaponin D
Catalog No.:BCN2760
CAS No.:206756-04-9
- Cannabichromene
Catalog No.:BCN4901
CAS No.:20675-51-8
- Pasiniazid
Catalog No.:BCC3835
CAS No.:2066-89-9
- 7-O-Methylporiol
Catalog No.:BCN3948
CAS No.:206560-99-8
- TB 21007
Catalog No.:BCC7510
CAS No.:207306-50-1
- Methyl sinapate
Catalog No.:BCN4675
CAS No.:20733-94-2
- 1,8-Bis(dimethylamino)naphtalene
Catalog No.:BCC8429
CAS No.:20734-58-1
- Saikosaponin C
Catalog No.:BCN1087
CAS No.:20736-08-7
- Saikosaponin A
Catalog No.:BCN1086
CAS No.:20736-09-8
- Dihydrosinapylalcohol
Catalog No.:BCN6542
CAS No.:20736-25-8
- 3-Bromocytisine
Catalog No.:BCC7705
CAS No.:207390-14-5
- MR 16728 hydrochloride
Catalog No.:BCC6684
CAS No.:207403-36-9
- Arteannuin L
Catalog No.:BCN4905
CAS No.:207446-89-7
- Arteannuin M
Catalog No.:BCN4906
CAS No.:207446-90-0
- Arteannuin N
Catalog No.:BCN4907
CAS No.:207446-92-2
- N-MPPP Hydrochloride
Catalog No.:BCC5672
CAS No.:207452-97-9
Fustin flavonoid attenuates beta-amyloid (1-42)-induced learning impairment.[Pubmed:19533734]
J Neurosci Res. 2009 Dec;87(16):3658-70.
Natural flavonoids ameliorate amyloid-beta peptide (Abeta)-induced neurotoxicity. We examined whether the Fustin flavonoid affects Abeta-induced learning impairment in mice. Repeated treatment with Fustin significantly attenuated Abeta (1-42)-induced conditioned fear and passive avoidance behaviors. This effect was comparable to that of EGb761, a standard extract of ginkgo. Fustin treatment significantly prevented decreases in acetylcholine (ACh) levels, choline acetyltransferase (ChAT) activity, and ChAT gene expression induced by Abeta (1-42). Fustin also consistently suppressed increases in acetyl cholinesterase (AChE) activity and AChE gene expression induced by Abeta (1-42). In addition, Fustin significantly attenuated Abeta (1-42)-induced selective decreases in muscarinic M1 receptor gene expression and muscarinic M1 receptor binding activity (as determined by [(3)H]pirenzepine binding) by modulating extracellular signal-regulated kinase 1/2 (ERK 1/2) and cAMP response-element binding protein (CREB) phosphorylation and brain-derived neurotrophic factor (BDNF) expression. These effects of Fustin were reversed by treatment with dicyclomine, a muscarinic M1 receptor antagonist, and SL327, a selective ERK inhibitor, but not by chelerythrine, a pan-protein kinase C (PKC) inhibitor. Taken together, our results suggest that Fustin attenuates Abeta (1-42)-impaired learning, and that the ERK/CREB/BDNF pathway is important for the M1 receptor-mediated cognition-enhancing effects of Fustin.
